Nature Search

A ganglioside-based immune checkpoint enables senescent cells to evade immunosurveillance during aging

This study identifies a novel immune checkpoint in senescent cells that is linked to the ganglioside GD3 and that contributes to the evasion of immune clearance by these cells and to aging and age-related diseases.

Charlène Iltis
Iryna Moskalevska
Julien Cherfils-Vicini
ResearchOpen Access27 Dec 2024
Nature Aging

Volume: 5, P: 219-236
Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity

Genomic, transcriptomic and epigenetic analyses of malignant pleural mesothelioma identify molecular axes and specialized tumor profiles underlying intertumoral heterogeneity.

Lise Mangiante
Nicolas Alcala
Lynnette Fernandez-Cuesta
ResearchOpen Access16 Mar 2023
Nature Genetics

Volume: 55, P: 607-618
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma

Changes in the tumour microenvironment have been associated with response and resistance to immunotherapy. Here, by performing longitudinal transcriptomic and spatial analysis, the authors report the exploratory analysis of their phase II trial of neoadjuvant chemotherapy alone or in combination with pembrolizumab (anti-PD1) in patients with advanced high-grade ovarian carcinoma.

Olivia Le Saux
Maude Ardin
Isabelle Ray-Coquard
ResearchOpen Access16 Jul 2024
Nature Communications

Volume: 15, P: 1-15
A NEW DYSMORPHIC SYNDROME WITH CNS, RENAL AND SKELETAL ABNORMALITIES

Holly H Ardinger
Stephen M Bonsib
James W Hanson
Research01 Apr 1984
Pediatric Research

Volume: 18, P: 303
Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors

The molecular nature of large-cell neuroendocrine lung carcinomas (LCNEC) has remained unclear. Here, the authors show LCNECs represent a distinct transcriptional subgroup among lung cancers and comprise two molecular subgroups, type I (TP53 and STK11/KEAP1 alterations) and type II (TP53 and RB1 inactivation).

Julie George
Vonn Walter
Roman K. Thomas
ResearchOpen Access13 Mar 2018
Nature Communications

Volume: 9, P: 1-13
Modelling mutational landscapes of human cancers in vitro

Magali Olivier
Annette Weninger
Jiri Zavadil
ResearchOpen Access27 Mar 2014
Scientific Reports

Volume: 4, P: 1-9
Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing

H Huskova
M Ardin
M Korenjak
ResearchOpen Access10 Jul 2017
Oncogene

Volume: 36, P: 6041-6048
Base changes in tumour DNA have the power to reveal the causes and evolution of cancer

M Hollstein
L B Alexandrov
J Zavadil
ReviewsOpen Access06 Jun 2016
Oncogene

Volume: 36, P: 158-167

Search

A ganglioside-based immune checkpoint enables senescent cells to evade immunosurveillance during aging

Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity

Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma

A NEW DYSMORPHIC SYNDROME WITH CNS, RENAL AND SKELETAL ABNORMALITIES

Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors

Modelling mutational landscapes of human cancers in vitro

Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing

Base changes in tumour DNA have the power to reveal the causes and evolution of cancer

Search

Quick links

Search

Filter By:

Search

Quick links